IP Library Granted Patent US 11,020,609
Granted Patent B2
US 11,020,609 · App. 16/693,840 · Granted Jun 1, 2021

Methods and compositions for treatment of pigmented lesions

Inventors: Remigio Piergallini (A.P., IT); Nikolaos Loupis (Athens, GR); Francesco Bellini (Calgary, CA)
Assignee: KLOX TECHNOLOGIES INC.
A61N5/062A01H5/10A61K8/22A61K8/492A61K8/498A61K8/60A61K8/735A61K8/736A61K31/17A61K31/352A61K31/353A61K31/403A61K31/404A61K31/4166A61K31/7008A61K31/728A61K31/737A61K33/40A61K41/0057A61K45/06A61K47/02A61K47/183A61K47/22A61K47/46A61N5/0616A61Q19/00A61Q19/08A61N2005/0662A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,020,609
App. No.
16/693,840
Granted
Jun 1, 2021
Kind
B2
Abstract

There is provided a method for treating pigmented lesions comprising a composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant. The composition may further comprise at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Claims (16)

1. A method for treating a pigmented lesion comprising:

a) topically applying on a patient's skin afflicted with a pigmented lesion, a composition comprising at least one oxidant, at least one fluorescent compound, and at least one healing factor selected from hyaluronic acid, glucosamine and allantoin; and

b) exposing said composition to actinic light having an emission wavelength between about 400 nm and 600 nm for a time sufficient to cause a change in color of the fluorescent compound.

2. The method according to claim 1 , wherein the pigmented lesion is selected from melanocytic proliferation and reticular melanotic hypermelanose.

3. The method according to claim 1 , wherein the pigmented lesion is a hyper pigmented lesion.

4. The method according to claim 3 , wherein the hyper pigmented lesion is a post-traumatic hyperpigmentation.

5. The method according to claim 1 , wherein said composition is exposed to actinic light for a period of about 60 seconds to about 5 minutes per cm 2 of an area to be treated.

6. The method according to claim 1 , wherein a source of actinic light is in continuous motion over an area to be treated.

7. The method according to claim 1 , wherein the at least one oxidant is selected from at least one of hydrogen peroxide, carbamide peroxide and benzoyl peroxide.

8. The method according to claim 1 , wherein the composition further comprises at least one hydrophilic gelling agent.

9. The method according to claim 8 , wherein the at least one hydrophilic gelling agent is selected from at least one of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, a carbomer polymer, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin and gelatin.

10. The method according to claim 1 , wherein the composition further comprises at least one chelating agent selected from ethylenediaminetetraacetic acid (EDTA) an ethylene glycol tetraacetic acid (EGTA).

11. The method according to claim 1 , wherein the composition further comprises at least one of rhodamine B, rhodamine WT, rhodamine G, phloxine B, rose bengal, eosin B, fluorescein, Erythrosine B, saffranin O, basic fuchsine, acid fuchsine, 3,3′-dihexylocarbocyanine iodide, carminic acid, indocyanine green, crocetin, alpha-crocin (8,8-diapo-8,8-carotenoic acid), zeaxanthine, lycopene, alpha-carotene, beta-carotene, merbromine, bixin, fucoxanthine, methyl violet, neutral red, para red, amaranth, carmoisine, allura red AC, tartrazine, orange G, ponceau 4R, methyl red, murexide-ammonium purpurate, pyronine Y and pyronine B.

12. The method according to claim 1 , wherein the composition further comprises at least one lipolysis stimulating factor selected from caffeine and paraxanthine.

13. The method according to claim 1 , wherein the fluorescent compound is eosin Y.

14. The method according to claim 1 , wherein the fluorescent compound is selected from a xanthene derivative dye, an azo dye, a biological stain and a carotenoid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2023
From: KLOX TECHNOLOGIES INC.
To: FLE INTERNATIONAL S.R.L.
Reel/Frame 063214/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 25, 2019
From: PIERGALLINI, REMIGIO; LOUPIS, NIKOLAOS; BELLINI, FRANCESCO
To: KLOX TECHNOLOGIES INC.
Reel/Frame 051104/0004 →
Continuity (8)
Continuation 16210034 · Dec 5, 2018
Continuation 15162801 · May 24, 2016
Continuation 14540484 · Nov 13, 2014
Continuation 14137599 · Dec 20, 2013
Continuation 13770907 · Feb 19, 2013
Division 13127445
Provisional Application 61112235 · Nov 7, 2008
Related Publication 20200330783A1 · Oct 22, 2020